These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37011522)

  • 1. Exploration of novel dihydroquinoxalinone derivatives as EGFR
    Cao Y; Lu X; Fu L; Shi T; Zhang C; Zeng L; Zhang J; Shao J; Xi J; Pan Z; Liu S; Zhu H
    Bioorg Chem; 2023 Jun; 135():106494. PubMed ID: 37011522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
    Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
    Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR
    Wang A; Shuai W; Wu C; Pei J; Yang P; Wang X; Li S; Liu J; Wang Y; Wang G; Ouyang L
    J Med Chem; 2024 Feb; 67(4):2777-2801. PubMed ID: 38323982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
    Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
    Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
    PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.
    Pei J; Wang G; Wang A; Wu C; Pan X; Shuai W; Bu F; Zhu Y; Wang Y; Ouyang L; Li W
    J Med Chem; 2023 Apr; 66(8):5719-5752. PubMed ID: 37042119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
    An B; Liu J; Fan Y; Nie W; Yang C; Yao H; Li W; Zhang Y; Li X; Tian G
    Bioorg Chem; 2022 May; 122():105743. PubMed ID: 35313239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
    Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
    Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR
    Fu J; Yu J; Zhang X; Chang Y; Fan H; Dong M; Li M; Liu Y; Hu J
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205605. PubMed ID: 37106478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.
    Zuo Y; Long Z; Li R; Le Y; Zhang S; He H; Yan L
    Eur J Med Chem; 2024 Feb; 265():116106. PubMed ID: 38169271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
    Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD9291 overcomes T790┬áM-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.